You lost weight fast, then the scale stopped moving three months ago. Before you assume the medication quit on you, a provider will want to see what your labs are actually saying—because a plateau is a data point, not a verdict.
Why a Plateau Isn't Automatically a Failure
When weight loss stalls, two very different things can be happening under the hood, and they call for different responses.
The first is metabolic adaptation. As body mass drops, so does total daily energy expenditure—partly because a smaller body burns fewer calories, and partly because the body defends its stored fat by downshifting metabolic rate and ramping up appetite signals. This is a well-documented physiological response to weight loss, not a personal failure of willpower [1].
The second is a pharmacologic ceiling: you've reached the practical limit of what a single-pathway drug is doing for you, and a different mechanism might change the math. Semaglutide is a GLP-1 receptor agonist—it acts on one incretin pathway. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it engages a second receptor system involved in glucose and appetite regulation [2][3].
Telling these apart is not something a refill portal can do. It's what a provider reads out of your bloodwork and your trend lines. This article is educational and is not medical advice; whether any medication is appropriate for you is a decision only an independent licensed provider can make.
Source: [2] FDA Prescribing Information: Tirzepatide injection (Highlights, warnings and adverse reactions), [3] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist — mechanism review, Endocrine Reviews / NIH PMC
What Fasting Insulin Actually Tells a Provider
Fasting insulin is one of the most underused numbers in a metabolic workup. It measures how hard your pancreas is working to keep glucose in range while you're fasting. A high fasting insulin with a normal fasting glucose is a classic early signature of insulin resistance—your body is compensating, and it's paying for that compensation with elevated insulin around the clock [4].
This matters for a stalled patient for a simple reason: insulin is a storage hormone. Chronically elevated insulin favors fat storage and can make the metabolic environment less friendly to fat loss. A provider who sees a high fasting insulin alongside a plateau is looking at a different problem than one who sees a normal insulin and a plateau.
Providers often pair fasting insulin with fasting glucose to estimate insulin resistance using HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), a calculation validated against more invasive gold-standard testing [5]. It's a directional read, not a diagnosis—but tracked over time, the trend is informative.
HbA1c: the slower, steadier signal
HbA1c reflects average blood glucose over roughly the prior three months, because glucose binds to hemoglobin in your red blood cells and stays there for the life of the cell. The American Diabetes Association uses HbA1c thresholds to classify normal, prediabetes, and diabetes ranges [6]. For someone on a metabolic protocol, a provider watches whether A1c is drifting the right direction, holding, or creeping—which tells them whether glucose control is improving even when the scale is stubborn.
Here's the part a lot of people miss: the scale can stall while your metabolic labs keep improving. If your A1c and fasting insulin are still moving in a healthy direction, the current tool may be doing real work that the scale isn't showing. That's a genuinely different situation than flat labs and a flat scale.
% HbA1c · marker = Prediabetes starts
The Ex-Athlete Problem: Are You Losing Muscle?
If you carry an athletic frame, the composition of what you're losing matters as much as the total. Any period of significant weight loss carries a risk of losing lean mass along with fat, and preserving muscle protects strength, metabolic rate, and long-term function [1].
This is why a good provider doesn't just chase a scale number. They'll want context: protein intake, resistance training, and ideally a body-composition read rather than raw weight. A plateau on the scale can actually be a *good* sign if you're adding lean mass while dropping fat—but you can't see that without measuring it. Labs plus composition is how a provider separates "the number stalled" from "the plan is failing."
How a Provider Weighs a Switch to Dual-Action
Switching from a GLP-1 agonist to a GIP/GLP-1 dual agonist is a clinical decision, not a checkbox. An independent provider is generally weighing questions like these:
- What do the trends say? Are fasting insulin, HOMA-IR, and HbA1c improving, flat, or worsening over the months on the current protocol?
- Is this adaptation or ceiling? A plateau with still-improving labs reads differently than a plateau with stalled labs.
- What's your tolerability history? GLP-1–class medications commonly cause gastrointestinal side effects—nausea, vomiting, diarrhea, constipation—especially early on. Your history with those matters [2].
- What are the safety flags? The GLP-1/GIP class carries labeling on risks including pancreatitis and gallbladder issues, and a boxed warning regarding thyroid C-cell tumors seen in rodents; personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication [2][3].
- What's the whole picture? Kidney function, other medications, and your goals all factor in.
A switch is never guaranteed, and no provider can promise a specific result. What they *can* do is read your actual numbers and tell you whether a different mechanism is a reasonable next step for you—or whether the smarter move is adjusting the plan you're on.
The Compounded Question
Many low-cost online protocols dispense compounded versions of these molecules. You should understand what that means before you stack another one on top of what you're paying.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
That's not a reason to panic—it's a reason to work with a provider who reviews your labs, monitors your response, and can explain the tradeoffs, rather than a vending-machine portal that just refills whatever you started with.
What to Bring to a Real Review
If you want a provider to give you a substantive read rather than "stay the course," show up with data:
- Recent fasting insulin and fasting glucose (for a HOMA-IR estimate)
- HbA1c, ideally with a prior value to show the trend
- A body-composition read if you have one, not just scale weight
- Your side-effect and tolerability history on your current protocol
- Your goals in plain terms—fat loss, strength preservation, or both
That's the difference between being managed by an algorithm and being reviewed by a clinician.
Where Velri fits
Velri is a technology and coordination company—it does not provide medical care. Velri can help coordinate the lab work (including fasting insulin, glucose, and HbA1c), connect you with an independent, licensed provider who reviews your numbers and history, and—if that provider determines a prescription is appropriate—coordinate fulfillment through an independent, licensed pharmacy. Care is delivered by independent provider groups; medications are dispensed by independent pharmacies. A prescription is never guaranteed and is always the decision of the independent provider. This article is educational and is not medical advice.
